Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

9 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human follicular lymphoma and normal lymphoid tissue comparisons

ABSTRACT: 20 FL lymph node samples from 16 patients and four normal lymphoid tissues (two tonsil and two spleen) from four different patient. Data can be viewed on the supplemental website at http://genome-www.stanford.edu/rituximab/.

ORGANISM(S): Homo sapiens

SUBMITTER: Janos Demeter

PROVIDER: E-SMDB-1845 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Variation in gene expression patterns in follicular lymphoma and the response to rituximab.

Bohen Sean P SP Troyanskaya Olga G OG Alter Orly O Warnke Roger R Botstein David D Brown Patrick O PO Levy Ronald R

Proceedings of the National Academy of Sciences of the United States of America 20030205 4

Analysis of the patterns of gene expression in follicular lymphomas from 24 patients suggested that two groups of tumors might be distinguished. All patients, whose biopsies were obtained before any treatment, were treated with rituximab, a monoclonal antibody directed against the B cell antigen, CD20. Gene expression patterns in the tumors that subsequently failed to respond to rituximab appeared more similar to those of normal lymphoid tissues than to gene expression patterns of tumors from ri ...[more]

PMID: 12571354

Similar Datasets

Follicular lymphoma and normal lymphoid tissue comparisons

Project description:20 FL lymph node samples from 16 patients and four normal lymphoid tissues (two tonsil and two spleen) from four different patient. Data can be viewed on the supplemental website at http://genome-www.stanford.edu/rituximab/. Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. Keywords: Logical Set

2005-11-23 | GSE3646 | GEO

Follicular lymphoma and normal lymphoid tissue comparisons

2005-11-22 | E-GEOD-3646 | biostudies-arrayexpress

Single cell RNA-sequencing of human tonsil Innate lymphoid cells (ILCs)

Project description:Single cell RNA-sequencing of human tonsil Innate lymphoid cells (ILCs) from three independent tonsil donors.

2016-01-27 | GSE70580 | GEO

Single cell RNA-sequencing of human tonsil Innate lymphoid cells (ILCs)

Project description:Single cell RNA-sequencing of human tonsil Innate lymphoid cells (ILCs) from three independent tonsil donors. Sequencing libraries were prepared from FACS sorted individual ILCs with the Smart-Seq2 protocol (Picelli et al. Nature Methods 2013)

2016-01-27 | E-GEOD-70580 | biostudies-arrayexpress

Variation in gene expression patterns in follicular lymphoma and the response to rituximab

Project description:This SuperSeries is composed of the following subset Series: GSE3646: Follicular lymphoma and normal lymphoid tissue comparisons GSE3647: Follicular lymphoma lymph node Abstract: Analysis of the patterns of gene expression in follicular lymphomas from 24 patients suggested that two groups of tumors might be distinguished. All patients, whose biopsies were obtained before any treatment, were treated with rituximab, a monoclonal antibody directed against the B cell antigen, CD20. Gene expression patterns in the tumors that subsequently failed to respond to rituximab appeared more similar to those of normal lymphoid tissues than to gene expression patterns of tumors from rituximab responders. These findings suggest the possibility that the response of follicular lymphoma to rituximab treatment may be predicted from the gene expression pattern of tumors. Refer to individual Series

2006-03-06 | E-GEOD-4351 | biostudies-arrayexpress

Human lymphoid stromal cell heterogeneity and functional alteration in follicular lymphoma

Project description:Despite recent advances in the characterization of stromal cell origin, heterogeneity, and function in mice, little is known in human. Follicular lymphoma (FL) is the most frequent indolent lymphoma. It corresponds to the accumulation of germinal center B-cell clones within lymph nodes. FL B cells interact with a reprogrammed immune and stromal cells that provide crucial contributions to the licensing of tumor growth and immune evasion. Most of transcriptomics approaches in human was performed on cultured, and amplified stromal cells modifying their phenotype and function. We purified native stromal cells from LN FL patients, healthy tonsil, and healthy bone marrow. Gene expression profiling based on three lymphoid stromal cell types provides new insights on the characterization of those cells in human and highlight new signalling pathways involved in the crosstalk between stromal cells and tumoral FL B cells.

2021-04-30 | GSE148656 | GEO

Variation in gene expression patterns in follicular lymphoma and the response to rituximab

Project description:Abstract: Analysis of the patterns of gene expression in follicular lymphomas from 24 patients suggested that two groups of tumors might be distinguished. All patients, whose biopsies were obtained before any treatment, were treated with rituximab, a monoclonal antibody directed against the B cell antigen, CD20. Gene expression patterns in the tumors that subsequently failed to respond to rituximab appeared more similar to those of normal lymphoid tissues than to gene expression patterns of tumors from rituximab responders. These findings suggest the possibility that the response of follicular lymphoma to rituximab treatment may be predicted from the gene expression pattern of tumors. This SuperSeries is composed of the SubSeries listed below.

2006-03-07 | GSE4351 | GEO

Evolution of advanced chronic lymphoid leukaemia unveiled by single-cell transcriptomics: a case study

Project description:Characterization of the transcriptional changes occurring at the single-cell level during the progression of a chronic lymphoid leukaemia treated with Rituximab, Fludarabine and Cyclophosphamide.

2020-10-27 | GSE150930 | GEO

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Project description:This pilot phase II trial studies the side effects and how well giving gemcitabine hydrochloride, carboplatin, dexamethasone, and rituximab together works in treating patients with previously treated lymphoid malignancies. Drugs used in chemotherapy, such as gemcitabine hydrochloride, carboplatin, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving more than one drug (combination chemotherapy) and giving monoclonal antibody therapy with chemotherapy may kill more cancer cells

| 2010075 | ecrin-mdr-crc

Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing

Project description:The impact of the microenvironment on innate lymphoid cell (ILC)-mediated immunity in humans remains largely unknown. Here we used full-length Smart-seq2 single-cell RNA-sequencing to unravel tissue-specific transcriptional profiles and heterogeneity of CD127+ ILCs across four human tissues. Correlation analysis identified gene modules characterizing the migratory properties of tonsil and blood ILCs, and signatures of tissue-residency, activation and modified metabolism in gut and lung ILCs. Trajectory analysis revealed potential differentiation pathways from circulating and tissue-resident naïve ILCs to a spectrum of mature ILC subsets. In the lung we identified both CRTH2+ and CRTH2- ILC2 with lung-specific signatures, which could be recapitulated by alarmin-exposure of circulating ILC2. Finally, we describe unique TCR-V(D)J-rearrangement patterns of blood ILC1-like cells, revealing a subset of potentially immature ILCs with TCR-d rearrangement. In summary, we provide publicly available data as a resource for in-depth understanding of ILC-mediated immunity in humans, with implications for disease.

2020-12-14 | GSE150050 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data